Binah Capital Group, Inc.

enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced its financial

gurufocus.com - 2026-06-15 10:00:00

SAN FRANCISCO--(BUSINESS WIRE)--Transcend, the autonomous "can I use this data?" platform that powers every data decision to scale customer growth, released The 2026 State of Customer Data in the World of AI, a report drawn from a survey of 228 senior IT and business leaders at enterprises with 5,000 or more employees.The findings reveal a widening gap between enterprise AI ambition and the data infrastructure required to support it. Despite Boston Consulting Group (BCG) projections that $2 tril.

businesswire.com - 2026-06-11 07:06:00

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that calderasib (MK-1084), an investigational oral specific KRAS G12C inhibi

gurufocus.com - 2026-05-29 07:00:00

AstraZeneca's IMFINZIÂ (durvalumab) in combination with Bacillus Calmette-GuÃrin (BCG) induction and maintenance therapy has been approved in the US for the

gurufocus.com - 2026-05-28 22:00:00

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca's IMFINZI® (durvalumab) in combination with Bacillus Calmette-Guérin (BCG) induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC). The approval by the Food and Drug Administration (FDA) is based on positive results from the POTOMAC Phase III trial which were presented at the European Society for Medical Oncology (ESMO) Congress 2025 and s.

businesswire.com - 2026-05-28 21:18:00

TVS Motor Company, part of TVS VENU, has been ranked #1 globally in the ‘Durable Consumer Goods' category in the annual ‘Best Stocks in the World', ranking

gurufocus.com - 2026-05-25 09:00:00

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepte

gurufocus.com - 2026-05-19 21:00:00

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherapy company, today announced results from two indirect treatm

gurufocus.com - 2026-05-19 08:00:00

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents

gurufocus.com - 2026-05-18 08:00:00

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement wit

gurufocus.com - 2026-05-16 14:00:00

- Assets Under Management (“AuM”) Increased 12.9% Year-over-Year to $29.0 Billion - - Increased Net Income to $1.9 Million from $1.0 million in the Prior Year - - Increased EBITDA [*] to $3.3 Million from $2.2 Million in the Prior Year - - Total Revenue of $48.7 million similar to $48.9 million in prior year period - NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Binah Capital Group, Inc. (“Binah”, “Binah Capital” or the “Company”) (NASDAQ: BCG; BCGWW), a leading financial services enterprise that owns and operates a network of industry-leading firms empowering independent financial advisors, today announced results for the quarter ended March 31, 2026. "I am pleased with our strong operational results in the first quarter, despite a sometimes challenging market, as this reflects the continuing growth of our differentiated platform,” stated Craig Gould, Chief Executive Officer of Binah Capital Group.

globenewswire.com - 2026-05-15 16:05:00

- High CR rates at any time observed in the CIS-containing population with 85.7% and 92.3% in the ITT population and Efficacy Evaluable population, respectively

globenewswire.com - 2026-05-15 08:00:00

TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients

globenewswire.com - 2026-05-15 07:00:00

More than 90% of patients surveyed who underwent bladder removal or received BCG report negative impact on most aspects of their lives Among patients treated with BCG, three- quarters describe managing the treatment- related physical symptoms as humiliating Patients and urologists point to the importance of advancing treatments that may better reflect patient preferences and quality-of-life considerations WASHINGTON, May 14, 2026 /PRNewswire/ -- A new global survey of patient and urologist perception and experience—conducted in collaboration with leading bladder cancer professional and patient organizations—reveals the physical, mental, and emotional toll associated with standard-of-care therapies for bladder cancer, including surgery to remove the bladder and Bacillus Calmette-Guérin (BCG) treatment. Released ahead of the American Urological Association (AUA) Annual Meeting, the findings highlight patient experiences that may not always be fully surfaced and discussed during care, pointing to opportunities to strengthen support and continue advancing innovative treatment approaches.

prnewswire.com - 2026-05-14 16:01:00

Positive 12-Month Phase 2 data for NDV-01 demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months in high-risk non-muscle invasive bladder cancer (NMIBC), and a 94% CR rate at any time and a durable 80% CR rate at 12 months in the BCG-unresponsive subpopulation, reinforcing best-in-class potential in NMIBC On track to initiate Phase 3 RESCUE registrational program in second line (2L) BCG-unresponsive and adjuvant intermediate-risk NMIBC in mid-2026 Filed provisional patent application with the USPTO in April 2026 covering NDV-01 pharmaceutical formulations and methods of treatment; if issued, patents claiming priority to the provisional filing would have a term until April 2047 Relmada will feature two NDV-01 presentations at the American Urological Association Annual Meeting (AUA2026), highlighting the 12-month Phase 2 data and the Phase 3 RESCUE program design and rationale Cash balance of $234.0 million as of March 31, 2026 expected to fund operations through 2029, including completion of the NDV-01 Phase 3 RESCUE program Management to host a conference call and webcast today at 4:30 PM ET CORAL GABLES, Fla., May 12, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported financial results for the first quarter ended March 31, 2026 and provided a corporate update.

globenewswire.com - 2026-05-12 16:05:00

-First results from CORE-008 Cohort CX Phase 2 Trial evaluating intravesical combination therapy in High-Risk BCG-Exposed and BCG-Unresponsive patients to be presented-

globenewswire.com - 2026-05-11 16:15:00